1
|
Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor. J Biosci 2018. [DOI: 10.1007/s12038-018-9805-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
2
|
MiR-146a functions as a small silent player in gastric cancer. Biomed Pharmacother 2017; 96:238-245. [DOI: 10.1016/j.biopha.2017.09.138] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2017] [Revised: 09/16/2017] [Accepted: 09/26/2017] [Indexed: 12/22/2022] Open
|
3
|
Fang Z, Zhang L, Liao Q, Wang Y, Yu F, Feng M, Xiang X, Xiong J. Regulation of TRIM24 by miR-511 modulates cell proliferation in gastric cancer. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2017; 36:17. [PMID: 28114950 PMCID: PMC5259882 DOI: 10.1186/s13046-017-0489-1] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Accepted: 01/05/2017] [Indexed: 12/20/2022]
Abstract
Background Increasing evidence highlights the important roles of tripartite motif containing 24 (TRIM24) in tumor initiation and malignant progression in many tumors, including gastric cancer (GC). Although TRIM24 expression is remarkably upregulated during GC carcinogenesis, the molecular mechanisms underlying TRIM24 dysregulation remain unexplored. Methods In this study, miRNA target prediction tools were applied to explore miRNAs that potentially target TRIM24. Western blot and quantitative reverse-transcriptase PCR (qRT-PCR) were performed to detected TRIM24 and miR-511 expression in GC tissues and cell lines. Dual-luciferase reporter assay was utilized to validate if TRIM24 is a direct target gene of miR-511. CCK-8 assay, cell colony formation assay, EdU incorporation assay and cell cycle analysis were performed to determine whether miR-511-mediated regulation of TRIM24 could affect GC progression. Results In our study, miR-511 was found to be downregulated in GC and an inverse correlation was observed between TRIM24 and miR-511 expression in primary GC tissues and cell lines. Dual-luciferase reporter assay further verified TRIM24 is a direct target of miR-511. Functional assays showed miR-511 overexpression inhibited cell growth, colony formation ability and cell cycle progression. Conversely, inhibition of endogenous miR-511 promoted these phenotypes in GC cells. Moreover, reintroduction of TRIM24 rescued miR-511-induced inhibitory effects on GC cells. Furthermore, miR-511 elicits tumor-suppressive effects through inactivating PI3K/AKT and Wnt/β-catenin pathways by suppressing TRIM24. Conclusions Our results provide the new evidence supporting the tumor-suppressive role of miR-511 in GC by suppressing TRIM24, suggesting that this novel miR-511/TRIM24 axis is critical in the control of gastric cancer tumorigenesis. Electronic supplementary material The online version of this article (doi:10.1186/s13046-017-0489-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Ziling Fang
- Department of Oncology, the First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Donghu District, Nanchang, 330006, Jiangxi Province, China
| | - Ling Zhang
- Department of Oncology, the First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Donghu District, Nanchang, 330006, Jiangxi Province, China
| | - Quan Liao
- Department of Oncology, the First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Donghu District, Nanchang, 330006, Jiangxi Province, China
| | - Yi Wang
- Department of Oncology, the First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Donghu District, Nanchang, 330006, Jiangxi Province, China
| | - Feng Yu
- Department of Oncology, the First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Donghu District, Nanchang, 330006, Jiangxi Province, China
| | - Miao Feng
- Department of Oncology, the First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Donghu District, Nanchang, 330006, Jiangxi Province, China
| | - Xiaojun Xiang
- Department of Oncology, the First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Donghu District, Nanchang, 330006, Jiangxi Province, China.
| | - Jianping Xiong
- Department of Oncology, the First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Donghu District, Nanchang, 330006, Jiangxi Province, China.
| |
Collapse
|
4
|
Wu Y, Yu J, Ma Y, Wang F, Liu H. miR-148a and miR-375 may serve as predictive biomarkers for early diagnosis of laryngeal carcinoma. Oncol Lett 2016; 12:871-878. [PMID: 27446362 PMCID: PMC4950576 DOI: 10.3892/ol.2016.4707] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2015] [Accepted: 03/18/2016] [Indexed: 12/29/2022] Open
Abstract
The role of microRNAs (miRs) as possible biomarkers and therapy targets has been extensively investigated in a number of types of cancer. However, the aberrant expression of miRs in laryngeal squamous cell carcinoma (LSCC), particularly during the progression of the disease, is poorly understood. In the present study, the role of miRs as possible novel early pre-diagnostic biomarkers of LSCC was investigated. TaqMan probe stem-loop quantitative polymerase chain reaction was utilized to accurately measure the amount of miR-148a and miR-375 in clinical samples of mild dysplasia, moderate dysplasia, severe dysplasia, cancer in situ, laryngeal cancer and normal epithelial controls. The application of miR-148a and miR-375 as potential predictive biomarkers for early diagnosis of LSCC was analyzed. The results of the present study suggested that miR-148a and miR-375 were significantly upregulated in LSCC tissues, and increased expression of miR-375 was associated with a more aggressive phenotype of LSCC. Additional investigation revealed that miR-148a and miR-375 increased during different dysplasia stages of LSCC carcinogenesis, and high-level expression of miR-148a or miR-375 in patients with laryngeal dysplasia may predict subsequent malignant transformation. miR-148a and miR-375 were significantly upregulated during LSCC carcinogenesis and may serve as possible predictive biomarkers for early diagnosis of LSCC.
Collapse
Affiliation(s)
- Ying Wu
- Department of Pathology, Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, P.R. China
| | - Jia Yu
- Department of Biochemistry and Molecular Biology, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China
| | - Yanni Ma
- Department of Biochemistry and Molecular Biology, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China
| | - Fang Wang
- Department of Biochemistry and Molecular Biology, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China
| | - Honggang Liu
- Department of Pathology, Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, P.R. China
| |
Collapse
|
5
|
Kadri F, LaPlante A, De Luca M, Doyle L, Velasco-Gonzalez C, Patterson JR, Molina PE, Nelson S, Zea A, Parsons CH, Peruzzi F. Defining Plasma MicroRNAs Associated With Cognitive Impairment In HIV-Infected Patients. J Cell Physiol 2016; 231:829-36. [PMID: 26284581 PMCID: PMC4758906 DOI: 10.1002/jcp.25131] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Accepted: 08/11/2015] [Indexed: 01/05/2023]
Abstract
Human Immunodeficiency Virus (HIV)-infected individuals are at increased risk for developing neurocognitive disorders and depression. These conditions collectively affect more than 50% of people living with HIV/AIDS and adversely impact adherence to HIV therapy. Thus, identification of early markers of neurocognitive impairment could lead to interventions that improve psychosocial functioning and slow or reverse disease progression through improved treatment adherence. Evidence has accumulated for the role and function of microRNAs in normal and pathological conditions. We have optimized a protocol to profile microRNAs in body fluids. Using this methodology, we have profiled plasma microRNA expression for 30 age-matched, HIV-infected (HIV(+) ) patients and identified highly sensitive and specific microRNA signatures distinguishing HIV(+) patients with cognitive impairment from those without cognitive impairment. These results justify follow-on studies to determine whether plasma microRNA signatures can be used as a screening or prognostic tool for HIV(+) patients with neurocognitive impairment. J. Cell. Physiol. 231: 829-836, 2016. © 2015 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Ferdous Kadri
- LSU Health Sciences Center, Medical School, Stanley S. Scott Cancer Center, New Orleans, LA 70112, USA
- Department of Microbiology, Immunology and Parasitology, New Orleans, LA 70112, USA
| | - Andrea LaPlante
- LSU Health Sciences Center, Medical School, Stanley S. Scott Cancer Center, New Orleans, LA 70112, USA
| | - Mariacristina De Luca
- LSU Health Sciences Center, Medical School, Stanley S. Scott Cancer Center, New Orleans, LA 70112, USA
| | - Lisa Doyle
- LSU Health Sciences Center, Medical School, Stanley S. Scott Cancer Center, New Orleans, LA 70112, USA
| | - Cruz Velasco-Gonzalez
- LSU Health Sciences Center, Medical School, Stanley S. Scott Cancer Center, New Orleans, LA 70112, USA
| | - Jonathan R. Patterson
- LSU Health Sciences Center, Medical School, Stanley S. Scott Cancer Center, New Orleans, LA 70112, USA
| | | | - Steve Nelson
- LSU Health Sciences Center, Medical School, Stanley S. Scott Cancer Center, New Orleans, LA 70112, USA
| | - Arnold Zea
- LSU Health Sciences Center, Medical School, Stanley S. Scott Cancer Center, New Orleans, LA 70112, USA
| | - Christopher H. Parsons
- LSU Health Sciences Center, Medical School, Stanley S. Scott Cancer Center, New Orleans, LA 70112, USA
| | - Francesca Peruzzi
- LSU Health Sciences Center, Medical School, Stanley S. Scott Cancer Center, New Orleans, LA 70112, USA
- Correspondence: Francesca Peruzzi, LSU Health Sciences Center, 1700 Tulane Avenue, New Orleans, LA 70112, , Tel: (504) 210-2978, Fax: (504) 210-2970
| |
Collapse
|
6
|
Dong XT, Huang Y, Li W, Shan WY, Zheng JN, Chen J. Diagnostic significance of Caspase 3 and Bcl-2 expression in colon cancer. Shijie Huaren Xiaohua Zazhi 2013; 21:3281-3285. [DOI: 10.11569/wcjd.v21.i30.3281] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To detect the expression of Caspase 3 and Bcl-2 in colon cancer and to analyze their diagnostic significance.
METHODS: Immunohistochemistry was used to detect the expression of Caspase 3 and Bcl-2 proteins in colon cancer, colon adenoma and normal colonic mucosa. The relationship between Caspase 3 and Bcl-2 protein expression with clinicopathological features of colon cancer was analyzed.
RESULTS: Compared with the normal colonic mucosa, the positive rate of Caspase 3 protein expression significantly declined in adenocarcinoma and adenoma (90.0% vs 50.0%, 48.5%, both P < 0.05) and that of Bcl-2 protein expression significantly increased (30.0% vs 83.4%, 66.7%, both P < 0.05) in adenocarcinoma and adenoma. Caspase 3 and Bcl-2 protein expression was significantly related to the degree of tumor differentiation (both P < 0.05) but not to other clinicopathological features. Expression of Caspase 3 was negatively correlated with that of Bcl-2 (r = -0.320, P < 0.05).
CONCLUSION: Bcl-2 can be used as a marker for evaluation of the malignancy of colon cancer. Bcl-2 functions in colon cancer possibly by restraining Caspase 3 activation.
Collapse
|
7
|
Epstein RJ. Has discovery-based cancer research been a bust? Clin Transl Oncol 2013; 15:865-70. [PMID: 24002944 DOI: 10.1007/s12094-013-1071-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Accepted: 06/18/2013] [Indexed: 12/11/2022]
Abstract
The completion of the human genome sequence sparked optimism about prospects for new anticancer drug development, but clinical progress over the last decade has proven slower than expected. Here it is proposed that unrealistically high expectations of first-generation discovery-based diagnostics have contributed to this problem. Hypothesis-based single-molecule tests (e.g., mutation screening of KRAS, EGFR, BRAF or KIT genes) continue to change clinical practice incrementally, whereas first-generation multiplex assays--such as gene expression profiling and proteomics--have identified few high-impact therapeutic targets despite numerous correlations with prognosis. To move forward, second-generation multiplex diagnostics should be based not on statistical patterns/associations alone, but on clinically interpretable ('high-signal-to-noise') data such as change-of-function mutations, gene amplifications, recurrent chromosomal anomalies, and abnormal phosphorylation profiles of ERK or mTOR signaling cascades.
Collapse
Affiliation(s)
- R J Epstein
- Department of Oncology, Clinical Cancer Informatics & Research Centre, The Kinghorn Cancer Centre, Sydney, Australia,
| |
Collapse
|
8
|
González-Masiá JA, García-Olmo D, García-Olmo DC. Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther 2013; 6:819-32. [PMID: 23874104 PMCID: PMC3711950 DOI: 10.2147/ott.s44668] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
The presence of small amounts of circulating nucleic acids in plasma and serum (CNAPS) is not a new finding. The verification that such amounts are significantly increased in cancer patients, and that CNAPS might carry a variety of genetic and epigenetic alterations related to cancer development and progression, has aroused great interest in the scientific community in the last decades. Such alterations potentially reflect changes that occur during carcinogenesis, and include DNA mutations, loss of heterozygosity, viral genomic integration, disruption of microRNA, hypermethylation of tumor suppressor genes, and changes in the mitochondrial DNA. These findings have led to many efforts toward the implementation of new clinical biomarkers based on CNAPS analysis. In the present article, we review the main findings related to the utility of CNAPS analysis for early diagnosis, prognosis, and monitoring of cancer, most of which appear promising. However, due to the lack of harmonization of laboratory techniques, the heterogeneity of disease progression, and the small number of recruited patients in most of those studies, there has been a poor translation of basic research into clinical practice. In addition, many aspects remain unknown, such as the release mechanisms of cell-free nucleic acids, their biological function, and the way by which they circulate in the bloodstream. It is therefore expected that in the coming years, an improved understanding of the relationship between CNAPS and the molecular biology of cancer will lead to better diagnosis, management, and treatment.
Collapse
Affiliation(s)
| | - Damián García-Olmo
- Department of Surgery, Universidad Autónoma de Madrid and La Paz University Hospital, IdiPaz, Madrid, Spain
| | - Dolores C García-Olmo
- Experimental Research Unit, General University Hospital of Albacete, Albacete, Spain
| |
Collapse
|
9
|
Pacifici M, Delbue S, Ferrante P, Jeansonne D, Kadri F, Nelson S, Velasco-Gonzalez C, Zabaleta J, Peruzzi F. Cerebrospinal fluid miRNA profile in HIV-encephalitis. J Cell Physiol 2013; 228:1070-5. [PMID: 23042033 DOI: 10.1002/jcp.24254] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2012] [Accepted: 09/27/2012] [Indexed: 12/14/2022]
Abstract
MicroRNAs are short non-coding RNAs that modulate gene expression by translational repression. Because of their high stability in intracellular as well as extracellular environments, miRNAs have recently emerged as important biomarkers in several human diseases. However, they have not been tested in the cerebrospinal fluid (CSF) of HIV-1 positive individuals. Here, we present results of a study aimed at determining the feasibility of detecting miRNAs in the CSF of HIV-infected individuals with and without encephalitis (HIVE). We also evaluated similarities and differences between CSF and brain tissue miRNAs in the same clinical setting. We utilized a high throughput approach of miRNA detection arrays and identified differentially expressed miRNAs in the frontal cortex of three cases each of HIV+, HIVE, and HIV- controls, and CSF of 10 HIV-positive and 10 HIV-negative individuals. For the CSF samples, the group of HIV+ individuals contained nine cases of HIV-associated neurological disorders (HAND) and, among those, four had HIVE. All the HIV-negative samples had non-viral acute disseminate encephalomyelitis. A total of 66 miRNAs were found differentially regulated in HIV+ compared to HIV- groups. The greatest difference in miRNA expression was observed when four cases of HIVE were compared to five non-HIVE cases, previously normalized with the HIV-negative group. After statistical analyses, 11 miRNAs were fund significantly up-regulated in HIVE. Although more clinical samples should be examined, this work represents the first report of CSF miRNAs in HIV-infection and offers the basis for future investigation.
Collapse
Affiliation(s)
- Marco Pacifici
- LSU Health Sciences Center, School of Medicine, Stanley S Scott Cancer Center, Louisiana State University, New Orleans, LA 70112, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Huang Y, Yang YB, Zhang XH, Yu XL, Wang ZB, Cheng XC. MicroRNA-21 gene and cancer. Med Oncol 2013; 30:376. [PMID: 23277281 DOI: 10.1007/s12032-012-0376-8] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2012] [Accepted: 09/14/2012] [Indexed: 12/20/2022]
Abstract
MicroRNAs (miRNAs) are a class of 18-27-nucleotides single-stranded RNA molecules that regulate gene expression at the post-transcriptional level. It has been demonstrated that miRNAs regulate a variety of physiological functions, including development, cell differentiation, proliferation, and apoptosis. There are growing evidence showed that miRNAs can affect the genesis and development of tumor and play a kind of tumor suppressor or oncogenic function by regulating its targetted gene-related signal pathway. miRNA-21 is one of the early discovered miRNAs in human cells, and the expression of miRNA-21 is significantly upregulated in different kinds of solid tumors. Its abnormal expression levels are closely associated with pathogenesis of cancers. This review summarizes the recent study on the field of miRNA-21 and its association with cancer.
Collapse
Affiliation(s)
- Yong Huang
- Animal Science and Technology College, He Nan University of Science and Technology, Luoyang City 471003, Henan Province, People's Republic of China.
| | | | | | | | | | | |
Collapse
|
11
|
Chatterton Z, Morenos L, Saffery R, Craig JM, Ashley D, Wong NC. DNA methylation and miRNA expression profiling in childhood B-cell acute lymphoblastic leukemia. Epigenomics 2012; 2:697-708. [PMID: 22122053 DOI: 10.2217/epi.10.39] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Acute lymphoblastic leukemia (ALL) is the most common cancer in children in the modern world. Recent efforts in characterizing the genetic contribution to this disease through uncovering gene mutations, deletions and structural variation by genome-scale methods have only accounted for a modest proportion of children with ALL. This suggests that either further genetic contributions to ALL have yet to be characterized or other factors, such as epigenetic aberrations are involved. A number of DNA methylation and miRNA profiling studies have investigated the role of both in childhood ALL. Here, we review these profiling efforts, summarize their major findings and speculate as to what the future may hold.
Collapse
Affiliation(s)
- Zac Chatterton
- Developmental Epigenetics, Early Development & Disease Theme, Murdoch Children's Research Institute, Melbourne, Australia
| | | | | | | | | | | |
Collapse
|
12
|
MicroRNA-146a is down-regulated in gastric cancer and regulates cell proliferation and apoptosis. Med Oncol 2011; 29:886-92. [PMID: 21347720 DOI: 10.1007/s12032-011-9862-7] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2011] [Accepted: 02/07/2011] [Indexed: 12/13/2022]
Abstract
Aberrant expression of microRNA-146a (miR-146a) has been reported to be involved in development and progression in various types of cancers, but its role in gastric cancer has not been fully elucidated. The purpose of this study was to investigate the levels of miR-146a expression and its function in human gastric cancer. Quantitative real-time polymerase chain reaction was used to detect the levels of miR-146a expression in gastric cancer tissue samples and cell lines. The cell growth rate of MKN-45 gastric cancer cells transfected with miR-146a mimics was examined by MTT assay. The effects of miR-146a on cell cycle and apoptosis were assessed by FACS analyses in MKN-45 cells. Thirty-six of 43 gastric cancer tissue samples (84%) showed decreased expression of miR-146a. We found low expression of miR-146a was correlated with increased tumor size (P = 0.006) and poor differentiation (P = 0.010) in gastric cancer. Overall survival time of patients with high miR-146a expression was significantly longer than that of patients with low expression of miR-146a (P = 0.011). The MTT assay showed that introduction of miR-146a inhibited cell proliferation in MKN-45 cells (P < 0.05). The proportion of apoptotic cells induced by transfection of miR-146a mimics were greater than that induced by transfection of the negative control mimics (11.9 vs. 5.9%). Our results suggested that miR-146a has potential as a novel suppressor gene in gastric cancer and its down-regulation may promote the progression of gastric cancer.
Collapse
|